The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension

Completed

• Conditions: Hypertension
• Interventions: Drug: Pritor (Telmisartan , BAY68-9291)

• Registration Number: NCT00471003
• Lead Sponsor: Bayer

Brief Summary

The main purpose of this study is to asses the efficacy and safety of telmisartan, with the special attention on the influence of telmisartan on selected metabolic parameters of patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-09
• Study First Submitted: 2007-05-07
• Study First Submitted QC: 2007-05-07
• Study First Posted: 2007-05-08
• Primary Completion: 2009-11
• Study Completion: 2009-11
• Status Verified: 2010-01
• Last Update Submitted: 2010-01-19
• Last Update Posted: 2010-01-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 5448

Inclusion Criteria

• Age over 18
• Untreated or ineffectively treated arterial hypertension

Exclusion Criteria

• Cholestatic disorders and severe hepatic failure
• Allergy to telmisartan
• Pregnancy and lactation period

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Arm 1	Pritor (Telmisartan , BAY68-9291)	-

Primary Outcome Measures

Name	Time	Method
Efficacy and safety of the treatment with telmisartan reported by the physician	At the both of planned control visits. (Approx. interval between visits 3 months)

Secondary Outcome Measures

Name	Time	Method
Changes in metabolic parameters in telmisartan treated patients	At the both of planned control visits. (Approx. interval between visits 3 months)